February 12, 2021Dear Cystinosis Community: We wanted to share an update from Leadiant Biosciences regarding the CYSTARAN® (cysteamine ophthalmic...
Read moreBy Cystinosis Research Network
February 15, 2021
In Honor of Laura’s 35th Birthday and Rare Disease Day. An article by Marybeth Krummenacker I was trying to...
Read moreBy Cystinosis Research Network
February 13, 2021
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in...
Read moreBy Cystinosis Research Network
February 9, 2021
News from Leadiant regarding new storage of Cystaran (cysteamine ophthalmic solution) 0.44%. Beginning December 22, 2025, shipments of Cystaran...
Read moreThe next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...
Read moreThe Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...
Read moreEmory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...
Read moreA new chapter in cystinosis research has begun. Novartis has officially opened the next phase of its CYStem Phase...
Read moreFor our families using Cystadrops, we received the following information from Recordati. This update was in response to direct...
Read more